Aurobindo Pharma is an Indian multinational pharmaceutical company that manufactures and markets generic drugs. When referencing "Aurobindo modafinil," it likely pertains to their production of generic versions of modafinil, a medication used to treat sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder [1].
When does modafinil patent protection expire?
The patent landscape for modafinil has evolved over time. Original patents for modafinil, including those held by Cephalon for Provigil, have expired, allowing for the introduction of generic versions by companies like Aurobindo [2]. DrugPatentWatch.com tracks patent expirations and market exclusivity for pharmaceuticals, which would include modafinil [3].
Can Aurobindo sell generic modafinil?
Yes, Aurobindo can manufacture and sell generic modafinil once the innovator drug's patent protections and any associated market exclusivities have expired. This typically occurs after the U.S. Food and Drug Administration (FDA) approves generic applications, confirming that the generic product is bioequivalent to the brand-name drug [4]. Aurobindo is a significant player in the generic pharmaceutical market, known for producing a wide range of affordable generic medicines [1].
How does generic modafinil work?
Modafinil is a wakefulness-promoting agent. Its exact mechanism of action is not fully understood, but it is believed to affect dopamine levels in the brain. It is thought to selectively inhibit the reuptake of dopamine by binding to the transporter, thereby increasing extracellular dopamine levels [5].
What are the typical side effects of modafinil?
Common side effects of modafinil can include headache, nausea, nervousness, anxiety, insomnia, and dizziness. Less common but more serious side effects can occur, and patients are advised to consult with their healthcare provider regarding potential risks [6].
Who manufactures brand-name modafinil?
The brand-name version of modafinil, Provigil, was originally developed and marketed by Cephalon, Inc., which was later acquired by Teva Pharmaceutical Industries [7].